- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Burkitt Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Mantle Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Essential Thrombocythemia, Extramedullary Plasmacytoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Meningeal Chronic Myelogenous Leukemia, Noncontiguous Stage II Mantle Cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Childhood Anaplastic Large Cell Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Childhood Anaplastic Large Cell Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Childhood Anaplastic Large Cell Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocyte Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- massage therapy, questionnaire administration, quality-of-life assessment, intervention by caregiver, standard follow-up care
- Procedure · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 1,033
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Abnormalities, Blood Coagulation Disorder, Brain Disease, Cerebrovascular Accident, Vascular Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Up to 45 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Pemetrexed
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Polycythemia Vera, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Rochester, Minnesota
- Conditions
- Immune Thrombocytopenia (ITP)
- Interventions
- Pirtobrutinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Hemophilia B
- Interventions
- SB-FIX
- Biological
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Anticoagulant-induced Bleeding, Coronary Syndrome
- Interventions
- Unfractionated heparin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Coagulation, Bleeding, Thrombosis
- Interventions
- Phytonadione (Vitamin K1)
- Drug
- Lead sponsor
- St. Joseph's Healthcare Hamilton
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- Westminster, Colorado • Albuquerque, New Mexico
- Conditions
- Menorrhagia, Blood Coagulation Disorders, Blood Platelet Disorders, Von Willebrand Disease, Hematologic Disease
- Interventions
- Tranexamic Acid, Desmopressin Acetate
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • East Lansing, Michigan • Rochester, Minnesota + 3 more
- Conditions
- Von Willebrand Diseases
- Interventions
- Von Willebrand Factor-Containing Product
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 66 Months and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Nonmalignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- anti-thymocyte globulin, busulfan, carboplatin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, thiotepa, total-body irradiation
- Biological · Drug · Radiation
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 4 Years to 70 Years
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Multifocal Lymphangioendotheliomatosis With Thrombocytopenia, Cutaneovisceral Angiomatosis With Thrombocytopenia, Vascular Anomaly With Thrombocytopenia, Hemangiomas
- Interventions
- no intervention
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Congenital Bleeding Disorder, Haemophilia B
- Interventions
- nonacog beta pegol
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 0 Years to 12 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 22 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Virtual Reality Distraction, Standard of Care Distraction
- Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 6 Years to 19 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Severe Hemophilia A
- Interventions
- rFVIIIFc
- Biological
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
- Conditions
- Hemophilia, AIDS
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years to 100 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 15
- States / cities
- La Jolla, California • Los Angeles, California • Indianapolis, Indiana + 11 more
- Conditions
- Hemophilia A
- Interventions
- Recombinant coagulation factor (rFVIIIFc)
- Biological
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Coagulopathy
- Interventions
- Resusix, FP24 (Frozen Plasma)
- Biological
- Lead sponsor
- Entegrion, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • St Louis, Missouri • Charlotte, North Carolina
- Conditions
- Hemophilia B
- Interventions
- CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua)
- Genetic
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 138 Months to 206 Months · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 6
- States / cities
- Orange, California • San Diego, California • Gainesville, Florida + 3 more
- Conditions
- Thrombotic Microangiopathy, Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
- Interventions
- Not listed
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- efgartigimod, Placebo
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
- Conditions
- Von Willebrand Disease
- Interventions
- Oprelvekin, Interleukin 11, IL-11
- Drug
- Lead sponsor
- Margaret Ragni
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Blood Coagulation Disorders, Hemorrhage
- Interventions
- Fresh frozen plasma transfusion
- Biological
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New Brunswick, New Jersey
- Conditions
- Hemophilia B
- Interventions
- AAV5-hFIXco-Padua (AMT-061)
- Genetic
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Sacramento, California • San Diego, California + 1 more